Member Info for iaintgotaclu

VOX MARKETS PODCAST on OTC now available at w w w.**********.co.uk

Boom seller done gaps all the way up to 2p

Someone who has been giving the Nod this will do a KOD or PYC

Bang on mate but if us small fry had the common we would be buying and be playing the the big boys at there own game and be getting massive upside like they say if you cannot beat em join em Massive buy

BOOM fill ya boots quick

Seems to be moving leaky leaky

https://twitter.com/mb_aim/status/946345360687026178

Twitter getting busy Justin Waite from V O X markets been buying in and a podast coming out very soon .... ramp bus and news coming

Word is TB has been contacted by MMs to sell but he has changed his stance and is saying NO now maybe got wind of something? all hearsay at the moment of course

TB Done selling keeping hold of the rest.... for the PYC Rerate

1 Mill trade delayed wow

After Admission tomorrow Shares % David Ciclitira and associated persons 1,2 26,946,608 55.9% Hyun Seok Kim 10,165,393 21.1% Clive Morton 2 4,166,667 8.6% Fortune Access Limited 3,000,000 6.2% Leaves just 8% freefloat

Babbler have you actually looked at what they are getting into and the freefloat here ?

yep will be massive

+11% 1 mill V 14 mill

Trading resumed this morning name change tomorrow and 1 million MC Vs 14 million

3.29 are buys

First Partner Deal Agreed with South Korean Partner Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular, announces its first partnering deal for ChondroMimetic(R) with a South Korean partner, Insung Medical Co. Ltd. ("Insung Medical"). Financial terms have not been disclosed. ChondroMimetic(R) is a minimally-invasive surgically placed scaffold for the repair of cartilage defects in the knee. The company is expecting results from an eight-year clinical extension study to be reported in Q1 2018. Insung Medical, based in the Wonju Medical Industry Techno Valley near Seoul, was originally established in 1984 and focuses on manufacturing and sales of consumable surgical products to domestic and overseas markets. Insung's existing product range and sales provides access to multiple local markets in South Korea. Subject to approval, ChondroMimetic(R) will be commercialised by Insung Medical in collaboration with the existing Collagen Solutions commercial office in Seoul which will also provide technical and educational support. Jamal Rushdy, CEO of Collagen Solutions, commented: "We are delighted to announce our first partnering deal with Insung Medical, providing early validation of the global commercial opportunity of ChondroMimetic(R). Insung Medical's enthusiasm for the opportunity to commercialise ChondroMimetic(R) in South Korea aligns with our strategy to launch the product to address the unmet need for a simple, cost-effective and long-term clinically effective treatment for cartilage defects." Mr. In Keum Song, Chairman of Insung Medical added: "I am very delighted to partner with Collagen Solutions for its ChondroMimetic product line. I look forward to a long term positive business relationship with Collagen Solutions as we expand into new technologies". Following the anticipated completion of the aforementioned extension study next quarter, Collagen Solutions and Insung Medical will collaborate to apply for approval by the Korean Ministry of Food And Drug Safety (MFDS) in parallel with Collagen Solutions' application for the CE Mark for European approval. Expected timing of such MFDS approval is not determined at this time. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Bang game on

days high just printed